We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Allarity

News List

Lantern Pharma Reacquires Irofulven from Allarity Therapeutics contractpharma
July 29, 2021
Allarity Therapeutics A/S and Lantern Pharma Inc. have entered an exclusive agreement under which Lantern will reacquire global rights to Irofulven (LP-100) and assume full responsibility for future clinical development and commercialization.
Allarity Therapeutics Receives Acceptance & Review Notification from U.S. FDA for Pre-Market Approval Application for Dovitinib-DRP firstwordpharma
July 06, 2021
Allarity Therapeutics A/S ("Allarity" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has provided a positive administrative acceptance and review notification for the Company's PMA application for its Dovitinib-DRP®